Results 241 to 250 of about 199,935 (297)

Causal correlations between inflammatory proteins and heart failure: A two‐sample Mendelian randomization analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1374-1385, April 2025.
Abstract Aims Inflammation plays a critical role in both the development and progression of heart failure (HF), which is a leading cause of morbidity and mortality worldwide. However, the causality between specific inflammation‐related proteins and HF risk remains unclear.
Xian‐Guan Zhu, Gui‐Qin Liu, Ya‐Ping Peng, Li‐Ling Zhang, Xian‐Jin Wang, Liang‐Chuan Chen, Yuan‐Xi Zheng, Xue‐Jun Xiang, Rui Qiao, Xian‐He Lin   +9 more
wiley   +1 more source

Novel markers of myocardial recovery in patients with left ventricular assist device: A cardiopulmonary exercise test and hemodynamic analysis. [PDF]

JHLT Open
Soydara C, Giverts I, Griskowitz CL, Landsteiner I, Drezek K, Minasian A, Logan TL, Camuso J, Dempsey AE, Milley K, Osho AA, Michel E, Coglianese E, Mastoris I, D'Alessandro DA, Jurgens CY, Lewis GD, Ton VK.   +17 more
europepmc   +1 more source

Semaglutide normalizes increased cardiomyocyte calcium transients in a rat model of high fat diet‐induced obesity

ESC Heart Failure, Volume 12, Issue 2, Page 1386-1397, April 2025.
Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira, Julia Theisen, Katharina J. Ermer, Marie Oertel, Anton Xu, David Weissman, Katharina Ecker, Jan Dudek, Martin Fassnacht, Alexander Nickel, Michael Kohlhaas, Christoph Maack, Ulrich Dischinger   +12 more
wiley   +1 more source

Method for Bioimpedance Assessment of Superficial Head Tissue Microcirculation. [PDF]

Sensors (Basel)
Briko A, Ryazantsev P, Gubko A, Kapravchuk V, Shchukin S, Akselrod B.   +5 more
europepmc   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Effects of remimazolam on hemodynamics in children with congenital heart disease undergoing cardiac catheterization. [PDF]

Front Pharmacol
Li H, Song Z, Jiang X, Liu W, Jiang Y, Wei R.   +5 more
europepmc   +1 more source

Ivabradine in acute care: Revisiting the funny current in critical care context. [PDF]

World J Crit Care Med
Mukesh A, Sharma A, Kothari N.
europepmc   +1 more source

Reimagining risk stratification: Dipeptidyl peptidase 3 in the new era of cardiovascular biomarkers. [PDF]

World J Cardiol
Ramoni D, Liberale L, Carbone F, Montecucco F.   +3 more
europepmc   +1 more source

Two causes of COVID‐19‐related myocardial injury‐associated cardiogenic shock: Myocarditis and microvascular thrombosis

ESC Heart Failure, Volume 12, Issue 2, Page 1514-1522, April 2025.
Takamasa Iwai, Hirohiko Aikawa, Yoshiaki Morita, Keiko Ohta‐Ogo, Teruo Noguchi   +4 more
wiley   +1 more source